Loading
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Previous close
$2.88
+$0.16 · +5.88%
Regular session · ET · Market data may be delayed.
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Day range
Current $2.88
52-week range
Current $2.88
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
68
Undervalued
Sentiment
53
Mixed
Risk
69
High Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Day range
Current $2.88
52-week range
Current $2.88
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 149.16M USD | 74.89M USD | 71.35M USD | 65.21M USD | 55.31M USD |
| Cost of goods sold | 76.85M USD | 20.73M USD | 19.64M USD | 15.48M USD | 11.65M USD |
| Gross profit | 72.31M USD | 54.16M USD | 51.71M USD | 49.72M USD | 43.66M USD |
| Research and development | 6.58M USD | 12.77M USD | 9.52M USD | 9.34M USD | 7.92M USD |
| Selling, general, and administrative | 97.16M USD | 75.95M USD | 72.74M USD | 75.5M USD | 63.3M USD |
| Operating expenses | 103.74M USD | 88.72M USD | 82.26M USD | 84.83M USD | 71.22M USD |
| Interest income | — | — | 24K USD | — | — |
| Interest expense | 8.42M USD | 7.29M USD | 5.42M USD | 3.6M USD | 3.3M USD |
| Depreciation and amortization | 3.47M USD | 2.07M USD | 2.01M USD | 1.65M USD | 1.06M USD |
| Operating income | −31.44M USD | −34.56M USD | −30.55M USD | −35.11M USD | −27.56M USD |
| Net income | −39M USD | −43.71M USD | −30.19M USD | −37.16M USD | −31.19M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
AdvisorShares Psychedelics ETFPSIL2.58M4.64%55.79M USD1.84%$24.86+1.10%
Vanguard Morningstar Total Stock Market ETFVTI2.09M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF948.35K0.00%93.7B USD0.05%$242.66+0.14%
iShares Micro-Cap ETFIWC263.78K0.02%1.47B USD0.60%$196.25+0.69%
Invesco NASDAQ Future Gen 200 ETFQQQS209.49K0.92%22.81M USD0.20%$44.7464+1.01%AdvisorShares Psychedelics ETFPSILVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
